Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this investigator initiated study is to identify the effects of intravitreal
brolucizumab on recurrence-free treatment intervals and morphological features in choroidal
neovascularizations (CNV) due to age-related macular degeneration (AMD) in which the Optical
coherence tomography (OCT) guided treatment interval failed to be extended to 6, 8 or 10
weeks intervals in a treat and extend regimen using aflibercept.